Axil Capital's Past News
GEXVal added to our portfolio companies.
Eurus Therapeutics added to our portfolio companies.
Cellusion added to our portfolio companies.
The Organization for Small & Medium Enterprises and Regional Innovation, JAPAN (“SMRJ”) announces investment of up to ¥2.0B in ALHF II.
Axil opens its Technology & Innovation Center.
Portfolio Companies' Past News
Perseus Proteomics presented an interim report on the PPMX-T003 Phase I study at the 65th American Society of Hematology (ASH) Annual Meeting.
GEXVal executed a third-party allotment of new shares.
Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema at American Academy of Ophthalmology.
The results of the joint research between Cranebio and Unicharm were distributed as a press release.
Cellusion was selected for the "Capital Investment Support Program for Breakthrough Business Promotion".
Cranebio has raised a total of 250 million yen through a Series A round.
United Immunity announced completion of fundraising and grant approval.
Techsomed announces FDA Clearance for Ablation Treatment Planning and Confirmation Software.
Jolly Good and Otsuka Pharmaceutical Launch New VR Employment Support Services! The SST-VR program "FACEDUO" is now expanding to vocational support centers and sheltered workshops.
Suono Bio has received an exclusive patent option from the Massachusetts Institute of Technology (MIT) for RoboCap.
Cellusion received MEXT Minister’s Award under the Award for Academic Startups 2023.
Japan's Minister of Health, Labor and Welfare experienced the employment support VR of Jolly Good.
Perseus Proteomics presented an interim report of the PPMX-T003 clinical trial at The 13th JSH International Symposium 2023
Suono Bio Reports Encouraging Results From a First in Human (FiH) Study of Its Ultrasound Mediated Drug Delivery Platform.
C4 Therapeutics Announces FDA Clearance of Investigational New Drug Appli-cation for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer.
Techsomed Announces Field Evaluation of its image guided ablation therapy software using GE HealthCare LOGIQ™ ultrasound systems at top US clinical sites.
Dr. Taku Kambayashi, founder of Abrax Japan, appeared on NTV's "Learning with Kazu-Laser.
Allgenesis Announces Encouraging Phase 1b Data Showing AG-80308 Providing Improvements in Multiple Signs and Symptoms in Dry Eye Patients.
Cellusion raises 2.83 Billion Yen (21 Million USD) in Series C Round.
Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial.
Luca Science gave a lecture at the Japan Society of Obstetrics and Gynecology (JSOG) and the presenter, Dr. Yosuke Matsumiya, received the JSOG Congress Award.
Perseus Proteomics reported that a Phase I study of PPMX-T003 confirmed the safety and efficacy of the drug in the first three patients treated with the drug.
Allgenesis Announces Last Patient Enrolled in the Phase 2a Trial Evaluating the Safety and Efficacy of AG-73305 in Diabetic Macular Edema (DME) Patients.
Himuka AM Pharma has completed a Phase I clinical trial of HM201 in Australia.
Cranebio presented at a conference on the development of rapid water quality testing in collaboration with Metawater, Co., Ltd.
Perseus Proteomics Completes PMDA Investigation of Aggressive NK Cell Leukemia Clinical Trial Plan Notification.
Ricoh Biomedical Startup Fund has decided to invest in United Immunity.
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC.
Jolly Good jointly developed medical VR with Harvard University Hospital to enter the U.S. market.
United Immunity has published an academic paper on UI-201.
LUCA Science was selected as one of the 2023 Deep Tech Top 10 by Forbes Japan magazine.
Suono Bio announces Formulation-Agnostic Platform for the delivery of RNA therapeutics.
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors.
An article on Perseus' Phase I study of PPMX-T003 in healthy subjects was published online in Clinical Pharmacology in Drug Development.
Suono Bio announces first patient dosed with its SuonoCalm™ Platform.
© Axil Capital All Rights Reserved
